Breakthrough research shows that stem cell genes can be edited in living systems
New research led by Harvard scientist Amy Wagers has demonstrated that gene-editing machinery can be delivered straight to stem cells where they live, rather than in a dish. Published in Cell Reports, the findings have major implications for biotechnology research and the development of therapeutics for genetic diseases.
“If you want to change a genome to correct a disease-causing gene mutation, you have to change it in the relevant stem cells,” said Wagers, the Forst Family Professor of Stem Cell and Regenerative Biology. “If you don’t change the stem cells, whatever cells you do fix may eventually be replaced with diseased cells fairly quickly. If you do fix the stem cells, they will create healthy cells that can eventually replace the diseased cells.”
But fixing stem cells is harder than it sounds. The way it works now, stem cells have to be extracted, kept alive and healthy, genetically altered, then put back in the patient’s body. The process is disruptive for the cells, which may ultimately be rejected or fail to engraft back into the patient.
Each type of stem cell lives in its own “niche,” well-protected in hard-to-reach areas such as bone marrow. “When you take stem cells out of the body, you take them out of the very complex environment that nourishes and sustains them, and they kind of go into shock,” Wagers said. “Isolating cells changes them. Transplanting cells changes them. Making genetic changes without having to do that would preserve the regulatory interactions of the cells — that’s what we wanted to do.”
Transport by virus
Wagers’ group used an adeno-associated virus (AAV) that infects human (and mouse) cells—but does not cause disease—as a transport vehicle. Building on their earlier work in mice with Duchenne muscular dystrophy, Wagers and her colleagues created various AAV packages to deliver gene-editing cargo into several different types of skin, blood, and muscle stem and progenitor cells.
“This was a true collaboration between labs specializing in several different organs,” said Jill Goldstein, a postdoctoral fellow in the Wagers lab and co-first author of the study. “We set up experiments in our organs of interest, analyzed them, compared notes, and made adjustments in a kind of scientific assembly line. None of us could have done it alone — it takes a lot of hands, and the team approach made it really fun.”
To test whether their AAV complexes managed to deliver, the researchers used mice that act as so-called reporter systems via a “reporter” gene that is normally silenced but can be turned on by gene editing. When the reporter gene is activated, the cell turns bright, fluorescent red.
Up to 60 percent effective
The researchers observed that in skeletal muscle, up to 60 percent of the stem cells turned fluorescent red. In cells that give rise to different types of skin cells, up to 27 percent of the cells turned red. Up to 38 percent of the stem cells in bone marrow (which make blood) were changed. That might seem low, but blood turns over so quickly that in some cases even a single healthy stem cell may be sufficient to rescue a defect.
“So far, the concept of delivering healthy genes to stem cells using AAV hasn’t been practical because these cells divide so quickly in living systems — so the delivered genes will be diluted from the cells rapidly,” said Sharif Tabebordbar, an alumnus of Harvard’s Department of Stem Cell and Regenerative biology and now a postdoctoral fellow at the Broad Institute. “Our study demonstrates that we can permanently modify the genome of stem cells, and therefore their progenies, in their normal anatomical niche. There is a lot of potential to take this approach forward and develop more durable therapies for different forms of genetic diseases. That includes different forms of muscular dystrophy, where tissue regeneration is such an important factor.”
“We looked at the skin of these AAV-transduced mice from the Wagers lab, and were pleased to see that many dermal cells were successfully edited as well,” said Ya-Chieh Hsu, Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology. “Those included cells that give rise to dermal adipocytes, and cells that help regulate other stem cells in the skin. We’ve always needed a tool that lets us manipulate dermal cells in vivo rapidly — so for us, this is like a dream come true.”
‘Things might start to move very quickly’
Delivering a gene therapy directly into a living system has been a barrier for biotech companies trying to develop therapies for diseases like spinal muscular atrophy.
“This is a really important resource for the community for two reasons,” Wagers said. “First, it changes the way we can study stem cells in the body. The AAV approach lets researchers investigate the importance of different genes for stem cells in their native environment, much more quickly than ever before. Because the delivery system is so robust, it can also be used to target genes that affect many different tissues.
“Secondly, it’s an important step toward developing effective gene therapies. The approach we developed gets around all the problems you introduce by taking stem cells out of a body and allows you to correct a genome permanently. AAVs are already being used in the clinic for gene therapy, so things might start to move very quickly in this area.”
Learn more: Editing genes at the source
The Latest on: Gene therapy
via Google News
The Latest on: Gene therapy
- Gene Therapy Market Size to Witness A CAGR Exceeding 40.7% By 2025 | Share Value, Growth Outlook, Regional Insights and COVID-19 Impact Analysison October 7, 2020 at 8:57 am
The Global Gene Therapy Market size was recorded at a value of USD 524 million in 2018 and is touted to register a CAGR of 40.7%. Global gene therapy market growth in gene therapy is due to various ...
- Pfizer commences late-stage study of hemophilia A gene therapyon October 7, 2020 at 4:06 am
Pfizer (NYSE:PFE) and licensor Sangamo Therapeutics (NASDAQ:SGMO) announce that the first patient has been dosed in a 63-subject Phase 3 clinical trial, AFFINE, evaluating gene therapy giroctocogene ...
- Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatmenton October 7, 2020 at 3:55 am
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of ...
- Gene Therapy Stocks - A Buying Opportunityon October 6, 2020 at 10:56 am
Some gene therapy stocks including ORTX, QURE and RGNX are trading considerably lower than in January of 2020.
- West Virginia Teenager Among First To Receive Gene Therapy Treatment For Rare Conditionon October 5, 2020 at 8:25 pm
A West Virginia teen is among the first in the country to get gene therapy treatment for a rare condition. Kendra Goins has Hurler Syndrome, meaning her body cannot break down certain types of sugar.
- Avrobio bags gene therapy to join Regenxbio and Sangamo in raceon October 5, 2020 at 6:00 am
Avrobio has licensed a Hunter syndrome lentiviral gene therapy from the University of Manchester. The deal positions Avrobio to join Regenxbio and Sangamo Therapeutics in the race to develop gene ...
- AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndromeon October 5, 2020 at 4:05 am
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced an exclusive, worldwide license agreement ...
- Gene Therapy Startups Extend Biotech’s Legacyon October 2, 2020 at 8:16 am
Every new biotech firm hopes to succeed like Genentech, the original biotech startup. Today, several new firms are focused on gene therapy challenges such as vector selection and manufacturing.
- Gene Therapy’s Renaissanceon October 2, 2020 at 8:16 am
Besides addressing lingering safety concerns, gene therapy is exploring applications beyond the correction of single-gene mutations. Possibilities include polygenic and gene-independent approaches.
- Global Gene Therapy Technologies, Markets & Companies Report 2020: Profiles of 202 Companies Presented with 266 Collaborationson October 1, 2020 at 1:30 pm
Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
via Bing News